Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Analysts say the number of private prescriptions for fat busting jabs like Ozempic in the UK are predicted to soar to over ...

Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

The former immigration minister, who lost four stone in 12 months, said the drug had aided him at the start of his bid to ...

Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex ...

This is an audio transcript of the Life and Art from FT Weekend podcast episode: ‘Fashion loves Ozempic. Should we talk about it?’ ...

The UK has become a “relatively small market” since leaving the European Union and must develop a different investment ...

Between Viking Therapeutics and Summit Therapeutics, investing $1,500 in Viking makes more sense right now, though it is a bit riskier, as it doesn't have a collaborator like Akesobio to pave the way ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.